Literature DB >> 19360396

Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock.

Sebastian Rehberg1, Christian Ertmer, Gabriele Köhler, Hans-Ulrich Spiegel, Andrea Morelli, Matthias Lange, Katharina Moll, Katrin Schlack, Hugo Van Aken, Fuhong Su, Jean-Louis Vincent, Martin Westphal.   

Abstract

PURPOSE: To compare the effects of first-line therapy with low-dose arginine vasopressin (AVP) or terlipressin (TP) on mesenteric blood flow, plasma AVP levels, organ function and mortality in ovine septic shock.
METHODS: Twenty-four adult ewes were anesthetized and instrumented for chronic hemodynamic monitoring. A flow-probe was placed around the superior mesenteric artery, and feces were extracted from the cecum. Following baseline measurements, feces were injected into the peritoneal cavity. When mean arterial pressure (MAP) decreased to less than 60 mmHg, animals were randomly assigned to receive AVP (0.5 mU kg(-1) min(-1)), TP (1 microg kg(-1) h(-1)) or saline (n = 8 each). A norepinephrine infusion was titrated to maintain MAP at 70 +/- 5 mmHg in all groups.
RESULTS: Cardiovascular pressures, cardiac output, mesenteric blood flow, and lung tissue concentrations of 3-nitrotyrosine and hemoxygenase-1 were similar among groups throughout the study period. TP infusion resulted in lower plasma AVP concentrations, reduced positive net fluid balance, increased central venous oxygen saturation and slightly prolonged survival compared to control and AVP-treated animals. However, TP treatment was associated with higher liver transaminases and lactate dehydrogenase versus control animals after 12 h.
CONCLUSIONS: This study provides evidence that the effects of low-dose TP differ from those of AVP, not only as TP has a longer half life, but also because of different mechanisms of action. Although low-dose TP infusion may be superior to sole norepinephrine or AVP therapy in septic shock, the safety of this therapeutic approach should be determined in more detail.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360396     DOI: 10.1007/s00134-009-1470-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  56 in total

1.  Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock.

Authors:  Gernot Marx; Samantha Pedder; Linda Smith; Seshapillai Swaraj; Steve Grime; Harold Stockdale; Martin Leuwer
Journal:  Crit Care Med       Date:  2006-12       Impact factor: 7.598

2.  Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study.

Authors:  Jacques Albanèse; Marc Leone; Anne Delmas; Claude Martin
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

3.  Beneficial effects of ethyl pyruvate in septic shock from peritonitis.

Authors:  Fuhong Su; Zhen Wang; Ying Cai; Myriam Remmelink; Jean-Louis Vincent
Journal:  Arch Surg       Date:  2007-02

4.  Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury.

Authors:  Fuhong Su; Nam Duc Nguyen; Jacques Creteur; Ying Cai; Nathalie Nagy; Hoang Anh-Dung; Andre Amaral; Frederico Bruzzi de Carvalho; Didier Chochrad; Jean-Louis Vincent
Journal:  Shock       Date:  2004-08       Impact factor: 3.454

5.  Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.

Authors:  Andrea Morelli; Monica Rocco; Giorgio Conti; Alessandra Orecchioni; Andrea De Gaetano; Giuliana Cortese; Flaminia Coluzzi; Enrico Vernaglione; Paolo Pelaia; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2003-12-12       Impact factor: 17.440

6.  Terlipressin in catecholamine-resistant septic shock patients.

Authors:  Marc Leone; Jacques Albanèse; Anne Delmas; Wajdi Chaabane; Franck Garnier; Claude Martin
Journal:  Shock       Date:  2004-10       Impact factor: 3.454

7.  Hemodynamic effects of titrated norepinephrine in healthy versus endotoxemic sheep.

Authors:  Matthias Lange; Katrin Bröking; Christoph Hucklenbruch; Christian Ertmer; Hugo Van Aken; Martin Lücke; Hans-Georg Bone; Martin Westphal
Journal:  J Endotoxin Res       Date:  2007

8.  Vasopressin versus norepinephrine infusion in patients with septic shock.

Authors:  James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

9.  Nitric oxide, oxidants, and protein tyrosine nitration.

Authors:  Rafael Radi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-12       Impact factor: 11.205

10.  Circulating vasopressin levels in septic shock.

Authors:  Tarek Sharshar; Anne Blanchard; Michel Paillard; Jean Claude Raphael; Philippe Gajdos; Djillali Annane
Journal:  Crit Care Med       Date:  2003-06       Impact factor: 7.598

View more
  21 in total

1.  Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia.

Authors:  Matthias Lange; Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Gabriele Köhler; Tim G Kampmeier; Hugo Van Aken; Martin Westphal
Journal:  Inflamm Res       Date:  2010-12-29       Impact factor: 4.575

2.  Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock.

Authors:  Andrea Morelli; Abele Donati; Christian Ertmer; Sebastian Rehberg; Alessandra Orecchioni; Alessandro Di Russo; Paolo Pelaia; Paolo Pietropaoli; Martin Westphal
Journal:  Intensive Care Med       Date:  2011-02-19       Impact factor: 17.440

3.  Terlipressin or norepinephrine in septic shock: do we have the answer?

Authors:  Mark D Williams; James A Russell
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

4.  Terlipressin or norepinephrine, or both in septic shock?

Authors:  Johan Mårtensson; Anthony C Gordon
Journal:  Intensive Care Med       Date:  2018-07-13       Impact factor: 17.440

5.  Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial.

Authors:  Florian Simon; Ricardo Giudici; Angelika Scheuerle; Michael Gröger; Pierre Asfar; Josef A Vogt; Ulrich Wachter; Franz Ploner; Michael Georgieff; Peter Möller; Régent Laporte; Peter Radermacher; Enrico Calzia; Balázs Hauser
Journal:  Crit Care       Date:  2009-07-10       Impact factor: 9.097

6.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

7.  Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis.

Authors:  Sebastian Rehberg; Yusuke Yamamoto; Linda Sousse; Eva Bartha; Collette Jonkam; Anthony K Hasselbach; Lillian D Traber; Robert A Cox; Martin Westphal; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-09-07       Impact factor: 4.733

8.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

9.  Arginine vasopressin in septic shock: supplement or substitute for norepinephrine?

Authors:  Sebastian Rehberg; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Crit Care       Date:  2009-08-14       Impact factor: 9.097

10.  Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-28       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.